Developing new treatments for neurological disorders caused by CACNA1A mutations
Towards Novel Therapies for CACNA1A Neurological Disorders
This study is looking at how changes in a specific gene can cause conditions like epilepsy and migraines, and it aims to create new treatments by using special cells from patients to better understand these disorders.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11035146 on NIH RePORTER |
What this research studies
This research investigates how mutations in the CACNA1A gene lead to various neurological disorders, including epilepsy and migraines. By analyzing the functional effects of these mutations, the team aims to categorize them into groups that can be targeted with specialized bioengineered therapies. The approach involves using patient-specific induced pluripotent stem cells to create neurons that mimic the conditions of these disorders, allowing for a better understanding of the underlying mechanisms and potential treatment options. The goal is to develop novel therapeutic molecules that can effectively address the specific functional deficits caused by these mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with conditions linked to CACNA1A mutations, such as familial hemiplegic migraine, episodic ataxia, or other related neurological disorders.
Not a fit: Patients without CACNA1A mutations or those with unrelated neurological conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to targeted therapies that significantly improve the quality of life for patients with CACNA1A-related neurological disorders.
How similar studies have performed: Previous research has shown promise in developing targeted therapies for genetic neurological disorders, suggesting that this approach could yield significant advancements.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Colecraft, Henry M. — Columbia University Health Sciences
- Study coordinator: Colecraft, Henry M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.